As of March 31, 2025, Tourmaline's (TRML, Financial) financial reserves, including cash, cash equivalents, and investments, totaled $275.3 million. This marks a decline from $294.9 million recorded on December 31, 2024. Despite this reduction, the company expects its available resources will sustain its operations well into the latter part of 2027. This financial runway is anticipated to support significant developments, such as key data readouts for pacibekitug in cardiovascular inflammation and thyroid eye disease (TED), along with other related projects.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Tourmaline Bio Inc (TRML, Financial) is $53.56 with a high estimate of $65.00 and a low estimate of $35.00. The average target implies an upside of 200.03% from the current price of $17.85. More detailed estimate data can be found on the Tourmaline Bio Inc (TRML) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Tourmaline Bio Inc's (TRML, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
